Jacobio Pharmaceuticals(01167.HK): First Patient Dosed in Phase IIa Clinical Trial of BET Inhibitor JAB-8263 for Rheumatoid Arthritis

NewTimeSpace News: On July 27, 2026, Jacobio Pharmaceuticals(01167.HK) issued an announcement, stating that the Phase IIa clinical trial of JAB-8263, a self-developed BET inhibitor of the Company, for the treatment of rheumatoid arthritis has finished first patient dosing in China.

As disclosed in the announcement, JAB-8263 is an oral highly potent BET inhibitor with global intellectual property rights. It exerts therapeutic effects on autoimmune diseases via epigenetic regulation. Preclinical studies indicate its potential therapeutic value for autoimmune disorders including rheumatoid arthritis (RA). This Phase IIa trial will evaluate its safety, tolerability, pharmacokinetic profiles and preliminary efficacy in patients with RA.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.